Stopped: The study was prematurely discontinued due to slow enrollment and strategic considerations. This decision was not based on any safety or efficacy concerns.
This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Clinical Success Rate at Day 7
Timeframe: Day 7 (from the data evaluated in approximately 21 months of the study)
Clinical Success Rate at Day 14
Timeframe: Day 14 (from the data evaluated in approximately 21 months of the study)
Clinical Success Rate at Day 21
Timeframe: Day 21 (from the data evaluated in approximately 21 months of the study)
Clinical Success Rate at Day 30
Timeframe: Day 30 (from the data evaluated in approximately 21 months of the study)
Clinical Success Rate at Day 60
Timeframe: Day 60 (from the data evaluated in approximately 21 months of the study)
Clinical Success Rate at End of Treatment (EOT)
Timeframe: At EOT (maximum 86 days of treatment exposure) (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate Based on the Evaluation by Site Investigator at Day 7
Timeframe: Day 7 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate Based on the Evaluation by Site Investigator at Day 14
Timeframe: Day 14 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate Based on the Evaluation by Site Investigator at Day 21
Timeframe: Day 21 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate Based on the Evaluation by Site Investigator at Day 30
Timeframe: Day 30 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate Based on the Evaluation by Site Investigator at Day 60
Timeframe: Day 60 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate Based on the Evaluation by Site Investigator at EOT
Timeframe: At EOT (maximum 86 days of treatment exposure) (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate Based on the Evaluation by Central Laboratory at Day 7
Timeframe: Day 7 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate Based on the Evaluation by Central Laboratory at Day 14
Timeframe: Day 14 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate Based on the Evaluation by Central Laboratory at Day 21
Timeframe: Day 21 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate Based on the Evaluation by Central Laboratory at Day 30
Timeframe: Day 30 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate Based on the Evaluation by Central Laboratory at Day 60
Timeframe: Day 60 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate Based on the Evaluation by Central Laboratory at EOT
Timeframe: At EOT (maximum 86 days of treatment exposure) (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate by Pathogen Based on the Evaluation by Site Investigator at Day 7
Timeframe: Day 7 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate by Pathogen Based on the Evaluation by Site Investigator at Day 14
Timeframe: Day 14 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate by Pathogen Based on the Evaluation by Site Investigator at Day 21
Timeframe: Day 21 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate by Pathogen Based on the Evaluation by Site Investigator at Day 30
Timeframe: Day 30 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate by Pathogen Based on the Evaluation by Site Investigator at Day 60
Timeframe: Day 60 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate by Pathogen Based on the Evaluation by Site Investigator at EOT
Timeframe: At EOT (maximum 86 days of treatment exposure) (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate by Pathogen Based on the Evaluation by Central Laboratory at Day 7
Timeframe: Day 7 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate by Pathogen Based on the Evaluation by Central Laboratory at Day 14
Timeframe: Day 14 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate by Pathogen Based on the Evaluation by Central Laboratory at Day 21
Timeframe: Day 21 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate by Pathogen Based on the Evaluation by Central Laboratory at Day 30
Timeframe: Day 30 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate by Pathogen Based on the Evaluation by Central Laboratory at Day 60
Timeframe: Day 60 (from the data evaluated in approximately 21 months of the study)
Microbiological Success Rate by Pathogen Based on the Evaluation by Central Laboratory at EOT
Timeframe: At EOT (maximum 86 days of treatment exposure) (from the data evaluated in approximately 21 months of the study)
Number of Participants According to Indication for Ceftazidime-Avibactam at Index Date
Timeframe: At index date (from the data evaluated in approximately 21 months of the study)
Number of Participants According to Source of Infection
Timeframe: At index date (from the data evaluated in approximately 21 months of the study)
Number of Isolated Strains
Timeframe: At baseline (from 7 days prior to index date until index date) (from the data evaluated in approximately 21 months of the study)
Number of Strains With Resistance to Ceftazidime-Avibactam and Other Antibiotic Drugs
Timeframe: At baseline (from 7 days prior to index date until index date) (from the data evaluated in approximately 21 months of the study)
Number of Carbapenem-Resistant Strains
Timeframe: At baseline (from 7 days prior to index date until index date) (from the data evaluated in approximately 21 months of the study)